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ABSTRACT
Objective: To examine the effects of interferon beta (IFN)-1b on all-cause mortality over 21
years in the cohort of 372 patients who participated in the pivotal randomized clinical trial (RCT),
retaining (in the analysis) the original randomized treatment-assignments.
Methods: For this randomized long-term cohort study, the primary outcome, defined before data
collection, was the comparison of all-cause mortality between the IFN-1b 250 g and placebo
groups from the time of randomization through the entire 21-year follow-up interval (intention-to-
treat, log-rank test for Kaplan-Meier survival curves). All other survival outcomeswere secondary.
Results: After a median of 21.1 years from RCT enrollment, 98.4% (366 of 372) of patients were
identified, and, of these, 81 deaths were recorded (22.1% [81 of 366]). Patients originally ran-
domly assigned to IFN-1b 250 g showed a significant reduction in all-cause mortality over the
21-year period compared with placebo (p  0.0173), with a hazard ratio of 0.532 (95% confi-
dence interval 0.314–0.902). The hazard rate of death at long-term follow-up by Kaplan-Meier
estimates was reduced by 46.8% among IFN-1b 250 g–treated patients (46.0% among
IFN-1b 50 g–treated patients) compared with placebo. Baseline variables did not influence the
observed treatment effect.
Conclusions: There was a significant survival advantage in this cohort of patients receiving early
IFN-1b treatment at either dose compared with placebo. Near-complete ascertainment, to-
gether with confirmatory findings from both active treatment groups, strengthens the evidence
for an IFN-1b benefit on all-cause mortality.
Classification of Evidence: This study provides Class III evidence that early treatment with
IFN-1b is associated with prolonged survival in initially treatment-naive patients with relapsing-
remitting multiple sclerosis. Neurology® 2012;78:1315–1322
GLOSSARY
16Y-LTF  16-Year Long-Term Follow-Up; 21Y-LTF  21-Year Long-Term Follow-Up; BOD  burden of disease; CI 
confidence interval; DMT  disease-modifying therapy; EDSS  Expanded Disability Status Scale; HR  hazard ratio;
IFN-1b interferon -1b; MSmultiple sclerosis; RCT randomized clinical trial.
Multiple sclerosis (MS) is a chronic, inflammatory disease of the CNS with a lifelong course,
necessitating outcome assessments over both the short term and long term.1 However, random-
ized clinical trials (RCTs) have typically focused only on short-term outcomes such as clinical
measures of relapse and physical disability, as well as MRI measures of disease activity and
severity.2–8 Although survival is the ultimate long-term outcome, to date mortality in patients
with MS treated with disease-modifying therapy (DMT) has not been well-studied, largely
because of the length and completeness of observation needed.9
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Despite these challenges, several indepen-
dent studies have demonstrated that the stan-
dardized mortality ratio is 2–3 times higher
for patients with MS than for control subjects
without MS in the general population,10–15
with differences emerging as early as 2–10
years after MS diagnosis.15 Although MS
seems to cause a significant survival disadvan-
tage, the impact of DMTs on longevity is un-
known. As a reflection of the underlying
safety and efficacy of treatment regimens, sur-
vival can be considered an integrated measure
of long-term outcome, one that could poten-
tially be influenced by early treatment. The
long-term follow-up study was therefore un-
dertaken to investigate the impact of early
treatment with interferon -1b (IFN-1b) on
survival up to 21.4 years after patient enroll-
ment in the pivotal IFN-1b trial.
METHODS Patients. From October 1, 2009, to December
15, 2010, we sought to identify each of the 372 patients from the
11 North American trial centers who participated in the pivotal,
randomized placebo-controlled RCT of IFN-1b in relapsing-
remitting MS.2,16,17 Cohort randomization at the time of the
original treatment assignment was maintained for the entire
21-year period and, as shown in table e-1 on the Neurology
Web site at www.neurology.org, treatment allocation cohorts
were well-balanced for all baseline demographic vari-
ables.2,16,17 All randomly assigned patients who were enrolled
(for any amount of time) in the pivotal IFN-1b trial were
eligible to participate. The inclusion criteria for the original
RCT have been published previously.2 In brief, treatment-
naive patients aged 18–50 years with an Expanded Disability
Status Scale (EDSS) score 5.5 and with 2 or more clinical
exacerbations within the previous 2 years, were randomly as-
signed to receive IFN-1b 50 g (n  125), IFN-1b 250 g
(n  124), or placebo (n  123) every other day. During the
RCT, patients were treated and prospectively followed for a pe-
riod of up to 5.1 years, with a median of 3.8 years (range 0.1–5.1
years) and a mean of 3.3  1.4 years on assigned treatment. At
the end of the pivotal RCT in 1993, subsequent use of DMTs
was at the discretion of patients and their physicians. Only
IFN-1b was available initially; after 1996, use of alternative
DMTs was possible.18
Standard protocol approvals, registrations, and patient
consents. The preplanned 21-Year Long-Term Follow-Up
(21Y-LTF) study (ClinicalTrials.gov Identifier: NCT01031459)
was conducted in accordance with good clinical practice guide-
lines. Appropriate written informed consent was obtained. The
steering committee, consisting of 6 neurologists, 1 internal med-
icine specialist, 1 neuropsychologist, and 2 biostatisticians, de-
veloped the study protocol. This protocol was approved by the
institutional review board or independent ethics committee at
each center.
Study procedures. Mortality status was determined by link-
age of patients to the National Death Index in the United States
and other public domain databases. To achieve the most com-
plete ascertainment possible, investigators also reviewed patient
charts, conducted in-person interviews, and initiated telephone
contact with patients or their proxies.
Study endpoints. The primary endpoint of the 21Y-LTF
was survival/mortality (all-cause mortality), comparing the
IFN-1b 250 g group with the placebo group (by original
treatment randomization using an intention-to-treat analysis),
approximately 21 years after RCT enrollment. As a secondary
outcome, we compared all-cause mortality between the IFN-1b
50 g group and the placebo group.
Statistical analysis. Data were analyzed in accordance with
a predefined statistical plan. Survival outcome was analyzed by
original treatment assignment during the RCT, using intention-
to-treat principles, the Kaplan-Meier method of time to death
from randomization, and a log-rank test using SAS (version 9.1).
Six patients whose vital status could not be identified were cen-
sored at their last observation. The predictive value of baseline
characteristics was assessed by unadjusted and adjusted Cox pro-
portional hazard regression models. Adjusted models included
both individual covariates and interactions with treatment. Base-
line clinical variables included gender, age at disease onset, dura-
tion of disease, EDSS score, and relapse rate. Baseline MRI
variables included T2 burden of disease (BOD), defined as the
area (cm2 per slice) of hyperintense lesions seen on T2-weighted
images, and third ventricular width (mm). Continuous variables
were dichotomized according to the variable’s median value. As a
sensitivity analysis, we also analyzed the data using continuous
variables.
Additional sensitivity analyses were performed to assess the
robustness of the results. First, we analyzed the time from onset
of clinical symptoms to death (rather than from RCT onset),
using the Kaplan-Meier log-rank test. Second, we analyzed the
joint influence of baseline variables and treatment on survival
using a multivariate Cox regression, with p  0.5 required to
enter the model and p  0.1 needed to remain in the model;
because of the question being addressed in this study, treatment
assignment during the RTC was forced into these models.19
Third, we reanalyzed the data, assuming that all nonidentified
patients in the IFN-1b–treated groups had died at the time of
their last observation and that all placebo-treated patients were
alive at the end of the 21Y-LTF. Fourth, we sequentially ex-
cluded all patients from the 2 sites with the highest mortality
rates and subsequently reanalyzed the data using these smaller
datasets.
RESULTS Patient identification and baseline characteristics.
Of the 372 patients enrolled in the pivotal
IFN-1b trial, only 6 patients (2 per group) were lost
to follow-up, such that 366 (98.4%) were included
in the 21Y-LTF study (figure 1). Of the 6 patients
who could not be identified, 3 withdrew from the
pivotal study within 3 months of RCT onset and are
therefore unlikely to have been influenced by treat-
ment assignment. The remaining 3 patients termi-
nated their participation after 1.2, 2.9, and 4.2 years.
Patient identification rates among the 11 study cen-
ters ranged from 89.3% to 100%. Of these 366 pa-
tients, 81 (22.1%) had died and 285 (77.9%) were
alive. Between the 16-Year Long-Term Follow-Up
(16Y-LTF) and 21Y-LTF studies, an additional 38
patients were identified, 7 of whom were found to be
deceased at the time of the 16Y-LTF trial. Deceased
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patients therefore represented 18.4% (7 of 38) of
those unidentified patients in the 16Y-LTF cohort, a
higher proportion than the 10.7% (35 of 328) origi-
nally reported.18 The median time from pivotal trial
randomization to 21Y-LTF was 21.1 years. There
were no notable differences in baseline characteristics
among the groups at the start of the RCT for the 366
patients identified at 21Y-LTF (table e-1).
Survival outcomes. Original randomization to
IFN-1b 250 g was associated with a significant
reduction in all-cause mortality over the 21Y-LTF
period compared with randomization to placebo (fig-
ure 2A), with a hazard ratio (HR) of IFN-1b 250 g
compared with that for placebo of 0.532 (95% con-
fidence interval [CI] 0.314–0.902; p  0.0173).
This represents a reduction in the hazard rate of dy-
ing by 46.8% (figure 2A). A similar result was ob-
served for the IFN-1b 50 g treatment arm, with
an HR of 0.540 (95% CI 0.318–0.915; p 
0.0202), representing a reduction in the hazard rate
of dying of 46.0% (figure 2B).
Predictive markers in the 21Y-LTF. Certain baseline
parameters were associated with longer survival, us-
ing univariate Cox models with dichotomized vari-
ables. These included assignment to IFN-1b 250 g
(HR 0.533, 95% CI 0.314–0.904; p  0.0195), as-
signment to IFN-1b 50 g (HR 0.537, 95% CI
0.317–0.910; p  0.0209), lower EDSS score (HR
0.628, 95% CI 0.399–0.989; p  0.0449;], lower
T2 BOD (HR 0.424, 95% CI 0.264–0.682; p 
0.0004), and smaller MRI ventricle size (HR 0.576,
95% CI 0.353–0.940; p  0.0272).
Bivariate regression models (using dichotomized
variables), which included treatment together with
each individual baseline variable, showed that gen-
der, T2 BOD, and MRI ventricle size, in addition to
treatment, influenced the risk of dying (table e-2). In
these models, the HR for the treatment effect on
mortality remained quite stable, ranging from 0.506
to 0.608 (table e-2). Thus, the treatment-related HR
was unchanged by the inclusion of baseline variables,
even when these variables were themselves associated
with an increased likelihood of mortality (table e-2).
Moreover, no significant or important interactions
were noted when baseline variables such as age were
analyzed continuously or dichotomized by median
values (data not shown). Thus, the association of
early IFN-1b therapy with mortality/survival was
independent of demographic and baseline clinical
and MRI disease parameters. The presence of neu-
tralizing antibodies against IFN-1b during the
RCT did not affect survival.
Sensitivity analyses. Analyzing the data from the on-
set of clinical symptoms (rather than from RCT on-
set) again showed that original randomization to
either IFN-1b 250 g or IFN-1b 50 g was asso-
ciated with a significant reduction in all-cause mor-
tality over the 21Y-LTF period compared with that
for placebo (figure 2, C and D). For the IFN-1b
250 g group, the HR compared with placebo was
Figure 1 Patient identification and vital status at 21-year-long-term follow-up
IFN-1b interferon -1b.
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0.495 (95% CI 0.289–0.847; p  0.0089). For the
IFN-1b 50 g group, the HR compared with pla-
cebo was 0.545 (95% CI 0.321–0.924; p 0.0223).
In the multivariate Cox regression analysis, the
treatment effect on mortality was maintained for
IFN-1b (table 1), and the HR remained stable for
the IFN-1b 250 g (0.533) and IFN-1b 50 g
(0.659) doses. In the IFN-1b 250 g group analy-
sis, gender and baseline T2 BOD were retained as
concomitant predictors of mortality, whereas in the
IFN-1b 50 g group analysis, baseline T2 disease
burden and age at disease-onset were retained (table
1). The same multivariate stepwise Cox regression
analyses using continuous variables (i.e., without di-
chotomization) showed that both IFN-1b 250 g
and IFN-1b 50 g had significant effects on mor-
tality (data not shown).
Analysis assuming that all nonidentified patients
in the IFN-1b–treated groups had died at the time
of their last observation and that all placebo-treated
patients were alive at the end of the 21Y-LTF showed
no significant impact on the findings in either of the
treated groups or the placebo group. A reanalysis of a
smaller dataset in which all patients at the 2 study
sites with the highest mortality rates were excluded
sequentially did not alter the findings.
DISCUSSION The clinical course of MS can evolve
over a period of 30 years or more,20,21 so that long-
term follow-up studies are necessary to define disease
progression and survival. To date, however, only nat-
ural history populations have been investigated in
studies of sufficient duration.11–13 Questions about
the impact of any DMTs on long-term outcomes
Figure 2 Kaplan-Meier survival curves for time from pivotal trial randomization to death and from onset of clinical symptoms to death
Survival from pivotal randomized controlled trial randomization over 21 years is shown for interferon -1b (IFN-1b) 250 g vs placebo (A) and IFN-1b 50
g vs placebo (B). Time from onset of clinical symptoms to death is shown for IFN-1b 250 g vs placebo (C) and IFN-1b 50 g vs placebo (D). Hazard
ratios (HRs) and 95% confidence intervals (CIs) are estimated using Cox proportional hazard models without stratification.
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remain unanswered. To provide data for the impact
of therapy on survival, we analyzed survival in pa-
tients 21 years after their enrollment into the original
IFN-1b RCT.
In the RCT, both doses of IFN-1b had signifi-
cant benefits relative to those of placebo, as deter-
mined by both clinical and MRI outcomes.2,17 These
benefits were most conspicuous for the subsequently
licensed IFN-1b 250 g dose.2,17 Nevertheless, the
fact that both doses of IFN-1b had a clear therapeu-
tic benefit becomes important when the possible
manner in which the original randomization scheme
has been imprinted on mortality outcomes was
considered.
In the 21Y-LTF study, 81 deaths were recorded;
the greatest number of which were observed among
individuals assigned to placebo. Thus, relative to that
for placebo, the hazard rate of death at 21Y-LTF was
reduced by 46.8% in the IFN-1b 250 g group
and by 46.0% in the IFN-1b 50 g group. The
virtually identical effect sizes, together with the ther-
apeutic benefits of both doses on short-term out-
comes,2,17 lend support to our observations. If these
survival outcomes were due to chance (i.e., from a
type I error), it could reflect an unusually high mor-
tality rate in the placebo arm or use of other treat-
ments during long-term follow-up. However,
counter to this possibility, the observed survival rate
in our placebo arm is consistent with reports from
natural history studies.10,12–15 For example, as shown
in figure e-1, the survival rate 29 years after disease
onset (70%) observed by others10 was essentially
identical to that in our placebo group (70.4%). Fur-
thermore, the medications taken after the end of the
pivotal study did not differ systematically.18 Taken
together, these observations support the notion that
there is a survival advantage after early exposure to
IFN-1b.
Despite several baseline variables being signifi-
cantly associated with earlier mortality in our univar-
iate regression models, the inclusion of these
variables in bivariate models did not alter the ob-
served HR for the treatment effect (table e-2). In
addition, although T2 disease burden, as well as
some other baseline covariates, proved predictive of
mortality, their effect was additive to the predictive
power of the treatment effect (table 1). Finally, fur-
ther sensitivity analyses did not alter our results. Each
of these observations supports an observed survival
benefit associated with therapy.
Importantly, the baseline variables (T2 BOD and
MRI ventricle size) associated with increased mortal-
ity are themselves markers of MS severity, suggesting
that these patients were dying due to advancing MS.
This notion is further supported by our observations
in the 21Y-LTF study: 78.3% (54 of 69) of patients
were determined to have died of MS-related causes,
as expected for deaths that occur at ages when other
causes of mortality are uncommon. Moreover, all ex-
cess deaths were in the MS-related category and, in
particular, were the result of pulmonary infections.
There are several key features regarding our trial,
which are critical to any evaluation of the validity of
the reported findings. These include the facts that we
had a very long follow-up period (21 years), that
our treatment allocation cohorts were randomized at
baseline, and that we achieved near-complete ascer-
tainment (98.4%) of the RCT cohort.22,23 In contrast
to this, previous long-term studies in MS have had
much shorter periods of follow-up (8–15 years) and
much less complete ascertainment of the original
RCT population (39.8%–68.2%).24–26 Reports
based on relatively short periods of follow-up or low
patient ascertainment rates have a high probability of
bias. A high ascertainment rate is critically important
for a rare event such as mortality, especially when we
consider that unidentified patient cohorts are likely
to be enriched with deceased individuals relative to
identified patient cohorts.27 We observed this in our
own work: the death rate in the unidentified patient
cohort in the 16Y-LTF study (18.4% [7 of 38]) was
higher than that observed in the identified cohort
(10.7% [35 of 328]).18 Moreover, the 5 years be-
tween the 16Y-LTF and 21Y-LTF studies resulted in
a doubling of the number of observed deaths (35 vs
81 deaths), increasing the precision of the estimates.
The results of the 21Y-LTF study extend the treat-
ment benefits first suggested in the 16Y-LTF study.
We also conclude that datasets examining survival
are less informative with greater numbers of “miss-
Table 1 Multivariate elimination Cox regression analysis of baseline variables
on time from randomized controlled trial randomization to death
IFN-1b HR (95%CI) p Value
250-g group
Treatment 0.533 (0.310–0.917) 0.0231
Baseline T2 burden of disease (<15.0 vs>15.0 cm2) 0.435 (0.246–0.770) 0.0043
Gender (female vs male) 0.531 (0.312–0.906) 0.0202
50 g groupa
Treatment 0.659 (0.383–1.135) 0.1329
Baseline T2 burden of disease (<15.0 vs>15.0 cm2) 0.330 (0.183–0.596) 0.0002
Disease onset age (<27.0 vs>27.0 y) 0.618 (0.358–1.065) 0.0829
Abbreviations: CI confidence interval; HR hazard ratio.
a Treatment forced into the model. Continuous variables were dichotomized according to
the variable’s median value at baseline. HRs are presented as the hazard in the first dichot-
omized group divided by that in the second. Thus, for example, for T2 burden of disease
(15.0 vs 15.0 cm2), the HR is the hazard in the (15.0) group divided by that in the
(15.0) group. For the regression analysis, entry into the model required p  0.5; p  0.1
was required to stay in the model.
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ing” patients, because the missing patients are en-
riched in deceased individuals.
In this study, both IFN-1b 50 g and IFN-1b
250 g seemed to have similar effects on survival
compared with those for placebo. Although the
effects were not as conspicuous in the IFN-1b
250 g group, IFN-1b 50 g still had a signifi-
cant therapeutic impact on both clinical and MRI
measures compared with placebo.2,17 The survival
benefit of IFN-1b may be attributable to effects
of IFN-1b, which are independent of the dose
difference between the groups (at least for some
outcome measures).
Moreover, although it is not known how
IFN-1b might enhance survival in patients with
relapsing-remitting MS, the precise mechanism
whereby IFN-1b effectively modulates MS disease
activity is also not known. Nevertheless, despite these
uncertainties, the well-documented effects of IFN
on the short-term clinical course of MS may still be
linked to its impact on mortality. For example, oxi-
dative stress may shorten life expectancy in patients
with MS through an enhancement of attack-related
tissue injury28–30 or by increasing comorbid condi-
tions such as septicemia or respiratory failure.31,32 It is
conceivable that the survival advantage conferred
by IFN-1b may be mediated through its antioxi-
dative properties.33 Regardless of this theoretical
possibility, however, considerably more work will
be necessary to understand fully the biologic basis
for these findings.
The total duration of original treatment exposure
during the RCT in the 21Y-LTF cohort is summa-
rized in table 2. After the RCT, the use of DMTs was
both optional and unmasked. Although the choice,
type, and duration of therapy among patients were
variable, until 1996, the only DMT available in the
United States and Canada was IFN-1b. After this
time, the type of treatment received could have var-
ied. Despite this possibility, at the time of the 16Y-
LTF (when data on treatment use were collected),18
the median medication use in this cohort was largely
restricted to IFN-1b (either 250 or 50 g): 6.9
years for the original placebo group, 13.6 years for
the original IFN-1b 50 g group, and 12.0 years
for the original IFN-1b 250 g group (table 2).
Thus, patients originally randomly assigned to pla-
cebo had less cumulative exposure to IFN-1b than
those originally assigned to either IFN-1b 50 g or
IFN-1b 250 g during the pivotal RCT (table 2).
Consequently, we cannot distinguish between the
possibility that the observed survival benefit was due
to an effect of early treatment and the possibility that
the benefit was due to a longer duration of IFN-1b
exposure.
Theoretically, varying treatments and drug holi-
days during the uncontrolled phase of the 21Y-LTF
should lessen any survival differences because these
variations are expected to blur the distinction be-
tween groups. This variance should therefore bias the
result toward the null hypothesis. Despite this theo-
retical possibility, we detected a large and clinically
important survival benefit associated with random-
ization to IFN-1b treatment (either dose) vs pla-
cebo. With near-complete patient ascertainment
(98.4%), randomized cohorts, the longest period of
follow-up for a treatment-exposed MS population,
and similar results from 2 parallel groups of IFN-
1b–treated patients, these data support the notion
that early use of IFN-1b improves survival in pa-
tients with MS.
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